17 withdrawn. 17 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Withdrawn 17 |
| Phase 3 | 3 | Withdrawn 3 |
| Phase 1 | 2 | Withdrawn 2 |
Follow Hydroxychloroquine: new trials by email Literature Review of Hydroxychloroquine trials Research Report on Hydroxychloroquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Hydroxychloroquine to Prevent CIPN Hydroxychloroquine - Breast Cancer, Gynecologic Cancer | Phase 2 | Withdrawn | University of Arizona | 2024-06-01 | 2024-03-08 | |
| #StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19 Hydroxychloroquine, Mannitol - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | 2022-01-01 | 2025-01-07 | |
| HYDROxychloroquine in Syndrome Primary AntiPhospholipid Plaquenil 200Mg Tablet, Placebo oral tablet - Antiphospholipid Syndrome in Pregnancy, Anticoagulants | Phase 2 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2021-07-09 | 2026-04-06 | |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) Hydroxychloroquine Sulfate 200 MG [Plaquenil], Azithromycin 250 MG Oral Capsule, Placebo oral tablet - COVID19, Hematologic Malignancy | Phase 2 | Withdrawn | Institut de cancérologie Strasbourg Europe | 2020-09-02 | 2020-09-04 | |
| PROphylaxis for paTiEnts at Risk of COVID-19 infecTion Hydroxychloroquine Sulfate 200 MG - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Cambridge University Hospitals NHS Foundation Trust | 2020-09-01 | 2021-03-08 | |
| Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19) Hydroxychloroquine, Placebo - COVID-19, SARS-CoV-2 | Phase 2 | Withdrawn | Oregon Health and Science University | 2020-08-01 | 2020-10-29 | |
| A Study of Combination Therapies to Treat COVID-19 Infection hydroxychloroquine, Azithromycin, Ritonavir - COVID, COVID-19 | Phase 2 | Withdrawn | ProgenaBiome | 2020-07-01 | 2021-04-08 | |
| HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19 Hydroxychloroquine and Azithromycin - Sars-CoV2 | Phase 2 | Withdrawn | Latin American Cooperative Oncology Group | 2020-06-30 | 2020-10-05 | |
| A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 Hydroxychloroquine, Placebo - COVID-19, COVID19 | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2020-05-05 | 2025-05-16 | |
| Asymptomatic COVID-19 Trial Hydroxychloroquine sulfate &Azithromycin, Placebo - SARS-CoV-2 Infection | Phase 2 | Withdrawn | Rutgers, The State University of New Jersey | 2020-05-05 | 2020-11-02 | |
| Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women hydroxychloroquine sulfate 200 MG, Placebo oral tablet - COVID-19, SARS-CoV-2 | Phase 2 | Withdrawn | Sir Mortimer B. Davis - Jewish General Hospital | 2020-05-01 | 2020-06-25 | |
| Test and Treat COVID 65plus+ Hydroxychloroquine, Placebo - SARS-CoV 2, COVID-19 | Phase 2 / Phase 3 | Withdrawn | University Hospital Tuebingen | 2020-04-21 | 2021-01-15 | |
| Preventing COVID-19 in Healthcare Workers With HCQ: A RCT Hydroxychloroquine, Vitamin C - Covid-19 | Phase 2 | Withdrawn | Stony Brook University | 2020-04-20 | 2020-11-02 | |
| Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore Hydroxychloroquine - COVID, Coronavirus | Phase 2 | Withdrawn | Montefiore Medical Center | 2020-04-01 | 2020-05-27 | |
| Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") Hydroxychloroquine (HCQ), Gedatolisib - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2019-02-26 | 2020-04-28 | |
| Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss Hydroxychloroquine (HCQ), Placebo - Recurrent Pregnancy Loss, Miscarriage | Phase 2 | Withdrawn | University of Utah | 2016-07-01 | 2016-08-12 |
COVID-19 (11) · Coronavirus Infections (3) · Breast Neoplasms (2) · Abortion, Spontaneous (1) · Disease Progression (1) · Hematologic Neoplasms (1) · Myelodysplastic Syndromes (1) · Peripheral Nervous System Diseases (1) · Vasculitis (1)
Abramson Cancer Center at Penn Medicine (1) · Assistance Publique - Hôpitaux de Paris (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland (1) · Institut de cancérologie Strasbourg Europe (1) · Latin American Cooperative Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · Montefiore Medical Center (1) · Oregon Health and Science University (1) · ProgenaBiome (1) · Rutgers, The State University of New Jersey (1) · Sir Mortimer B. Davis - Jewish General Hospital (1) · Stony Brook University (1) · University Hospital Tuebingen (1) · University of Arizona (1)
United States (8) · France (2) · Brazil (1) · Germany (1) · Switzerland (1)
Angela DeMichele, MD (1) · Bayard Powell, MD (1) · Blaise Genton, MD-PhD (1) · Genovefa Papanicolaou, MD (1) · Jeffrey L Carson, MD (1) · Jennifer Segar, MD (1) · Marcel Curlin, MD (1) · Mary-Anne Hartley, MD, PhD MPH (1) · Priya Nori, MD (1) · Robert Silver, MD (1) · Sabine Hazan, MD (1) · Thomas Borody, MD, PhD, (1) · Thomas Hiemstra, PhD (1)
P30CA012197 (1)